PT009 is a budesonide and formoterol fumarate metered-dose inhaler (BFF MDI) studied in COPD clinical trials. It was evaluated in randomized, double-blind studies in subjects with moderate to severe COPD to assess efficacy and safety, and trial records list the study as complete.
AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma patients, showing statistically significant improvements over dual-combination therapies. Deutsche Bank maintained a Sell rating with a £115 price target.
Phase III KALOS and LOGOS trial results published in The Lancet Respiratory Medicine show Breztri Aerosphere improved lung function and reduced severe asthma exacerbations compared to dual-combination therapies in patients with uncontrolled asthma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02189304 |
Pharmacokinetics and Safety Study of PT010 in Healthy Subjects |
COMPLETED | PHASE1 |
